A New Chapter in a 27-Year Legacy

 What happens when nearly 3 decades of scientific excellence meet a new era of global collaboration?

CardioRisk 2025 delivered the answer with remarkable clarity.  Held in Alexandria from 12–15 November, the conference welcomed 452 physical attendees, alongside a distinguished lineup of 10+ international experts, joint and endorsed by the International Atherosclerosis Society (IAS), European Atherosclerosis Society (EAS) and the Austrian Society of Cardiology (ASC) reaffirming its position as one of the region’s most relevant and impactful platforms for cardiovascular risk reduction.

This year’s edition marked a milestone moment for the Egyptian Association of Vascular Biology & Atherosclerosis (EAVA), bringing together experts, clinicians, researchers, and industry leaders to exchange knowledge, challenge existing paradigms, and explore innovative solutions for today’s most pressing cardiovascular challenges.

A Scientific Program Designed for Impact
CardioRisk 2025 unfolded through a rich and well-curated agenda that blended advanced science, clinical practice, and multidisciplinary perspectives. The program covered a wide spectrum of cardiovascular risk factors, including dyslipidemia, atherosclerosis, heart failure, hypertension, obesity, and diabetes — ensuring that every participant left with practical, applicable insights.

Key Highlights Included:
– IAS Pre-Conference Course
Exploring rare lipid disorders, regression of atherosclerosis, and emerging lipid-lowering therapies — with contributions from leading authorities such as Peter Libby (USA), Khurram Nasir (USA), Raul Santos (Brazil), and Samia Mora (USA).

– International Lipid Summit
A powerful session that unpacked the newest discoveries in inflammation, neutrophil extracellular traps, and Lp(a) — led by global experts from Greece, Italy, and Egypt.

– Joint Sessions with IAS, EAS & the Austrian Society of Cardiology
Reinforcing CardioRisk’s international reach and scientific credibility.

– Game-Changing Trials I, II & III
A signature CardioRisk feature that brought the newest clinical evidence directly into practice, covering trials such as ALPACA, ESSENCE, TOP-STEMI, DIGIT-HF, PULSE, ZENITH, and many more.

– Workshops on Obesity, Diabetes & Myocardial Work
Hands-on and practice-driven, these sessions focused on essential clinical skills and modern diagnostic tools.

– Industry-Supported CME Sessions
Delivered by leaders like Sanofi, AstraZeneca, Novartis, Menarini, Novo Nordisk, Pharco, and Servier, adding significant educational value to the meeting.

A Global Faculty of Renowned Experts
The presence of international speakers from USA, Italy, Greece, Lebanon, Bahrain, South Africa, Austria, Brazil, and more gave CardioRisk 2025 an unmistakably global perspective.

Their contributions elevated discussions on lipid metabolism, inflammation, cardiovascular imaging, obesity management, and precision cardiovascular prevention.

This strong international participation solidified CardioRisk’s reputation as a regional hub for high-level cardiovascular dialogue.

“CardioRisk 2025 marks a new chapter in a 27-year journey built on knowledge, collaboration, and a shared commitment to better cardiovascular health. This year, we expanded our scientific horizon to include not only lipidology but a wider spectrum of cardiovascular risk factors — all supported by a distinguished international faculty. I am proud of the strong engagement and the meaningful discussions that shaped this edition. My sincere appreciation goes to all participants, partners, and contributors who helped deliver an inspiring, impactful, and future-driven meeting”, quoted Prof. Ashraf Reda – President of EAVA & CardioRisk.

“CardioRisk 2025 delivered exactly what our cardiovascular community needs at this moment — science that is relevant, practical, and driven by real clinical challenges. The strength of this year’s program came from the depth of discussions, the diversity of expertise, and the high-quality engagement from both local and international faculty. I am proud to see CardioRisk evolve into a true platform for collaboration and continuous learning, and I extend my sincere appreciation to everyone who contributed to this successful edition”, stated Prof. Atef Elbahry – Conference Vice President.

“Every session at CardioRisk 2025 reflected our commitment to advancing cardiovascular prevention and supporting physicians with updated, evidence-based knowledge. The active participation, strong scientific exchange, and excellent organization made this year’s meeting one of our most impactful editions to date. It was an honor to work with such a dedicated team and scientific board, and I look forward to building on this success in the coming years”, added Prof. El Sayed Farag – Conference General Secretary.

A Conference that Moves Science Forward
CardioRisk 2025 succeeded in providing attendees with:

• Updated guidelines and real-world applications
• Breakthroughs in lipid-lowering therapies including PCSK9 inhibitors, bempedoic acid, Lp (a) management, and novel triglyceride-lowering agents
• Insights into the interplay between inflammation, genetics, obesity, and cardiovascular disease
• Clinical case discussions and imaging-based decision-making tools
• Forward-looking approaches integrating AI, molecular therapies, and multidisciplinary prevention

Each session reflected CardioRisk’s mission: enhancing patient outcomes by empowering physicians with the latest, most practical cardiovascular knowledge.

The Power Behind the Experience — ICOM Group
Behind the success of CardioRisk 2025 stood the commitment and operational excellence of ICOM Group, whose team ensured every element of the conference ran with precision, professionalism, and purpose. From seamless scientific coordination and speaker management to flawless logistics, audiovisual operations, partner relations, and on-ground execution, ICOM team delivered an experience that matched the scientific value of the meeting.

Looking Ahead
With its rich content, strong international presence, and outstanding engagement, CardioRisk 2025 has reaffirmed its role as a scientific leader in cardiovascular risk prevention.

The conference once again highlighted the importance of collaboration — locally, regionally, and globally — in reducing the burden of cardiovascular disease and improving patient lives.

As the field continues to evolve, CardioRisk remains committed to driving innovation, education, and excellence for years to come.